RRMS: Natalizumab improves work ability during first year of treatment

Key clinical point: One year of natalizumab treatment in relapsing-remitting multiple sclerosis (RRMS) improved absenteeism and work productivity loss.

Major finding: One year of natalizumab exposure showed an early improvement in absenteeism scores (mean change, −4.2; P = .0190) and the work productivity loss scores (mean change, −7.2; P = .0456).

Study details: The data come from the WANT observational study of 91 Italian patients with RRMS.

Disclosures: The WANT study was funded by Biogen. The authors reported relationships with various pharmaceutical companies.

Source: Capra R et al. Neurol Sci. 2020 Nov 17. doi: 10.1007/s10072-020-04838-z.

Key clinical point: One year of natalizumab treatment in relapsing-remitting multiple sclerosis (RRMS) improved absenteeism and work productivity loss.

Major finding: One year of natalizumab exposure showed an early improvement in absenteeism scores (mean change, −4.2; P = .0190) and the work productivity loss scores (mean change, −7.2; P = .0456).

Study details: The data come from the WANT observational study of 91 Italian patients with RRMS.

Disclosures: The WANT study was funded by Biogen. The authors reported relationships with various pharmaceutical companies.

Source: Capra R et al. Neurol Sci. 2020 Nov 17. doi: 10.1007/s10072-020-04838-z.

Key clinical point: One year of natalizumab treatment in relapsing-remitting multiple sclerosis (RRMS) improved absenteeism and work productivity loss.

Major finding: One year of natalizumab exposure showed an early improvement in absenteeism scores (mean change, −4.2; P = .0190) and the work productivity loss scores (mean change, −7.2; P = .0456).

Study details: The data come from the WANT observational study of 91 Italian patients with RRMS.

Disclosures: The WANT study was funded by Biogen. The authors reported relationships with various pharmaceutical companies.

Source: Capra R et al. Neurol Sci. 2020 Nov 17. doi: 10.1007/s10072-020-04838-z.